<DOC>
	<DOCNO>NCT00004500</DOCNO>
	<brief_summary>OBJECTIVES : Evaluate safety efficacy lucinactant administer bronchoalveolar lavage ( BAL ) treatment meconium aspiration syndrome ( MAS ) newborn infant .</brief_summary>
	<brief_title>Phase III Randomized Study Lucinactant Full Term Newborn Infants With Meconium Aspiration Syndrome</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm . Arm I : Patients receive lucinactant bronchoalveolar lavage , right left lung , follow lung drainage . Treatment repeat patient stabilizes every 15 minute 2 course . Arm II : Patients receive standard treatment include oxygen , conventional mechanical ventilation , sedation , paralysis , vasopressor , alkalinization . Patients follow 12 month .</detailed_description>
	<mesh_term>Meconium Aspiration Syndrome</mesh_term>
	<mesh_term>Pulmonary Surfactants</mesh_term>
	<criteria>Diagnosis meconium aspiration syndrome ( MAS ) Continuous mechanical ventilation ( CMV ) time entry Enrollment within 48 hour birth Gestational age ≥ 37 week Oxygenation index ≥ 5 ≤ 30 Written informed consent sign dated infant 's parent ( ) legal guardian ( ) Congenital anomaly likely affect primary secondary endpoint Uncontrollable air leak Hydrops fetalis Rupture ≥ 3 week fetal membrane Evidence overwhelm bacterial infection time randomization Markedly labile persistent pulmonary hypertension time randomization Profound neurologic manifestation Sustained postductal SpO₂of &lt; 87 % ≥ 15 minute FiO₂of 1.00</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>48 Hours</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>meconium aspiration syndrome</keyword>
	<keyword>rare disease</keyword>
</DOC>